Avalo Therapeutics, Inc. current report, 07 May 2020

SEC Filing Summary: Cerecor Inc. (CERC)

Business Context and Reporting Period

This Form 8-K was filed by Cerecor Inc. on May 7, 2020. The filing serves to announce the company's financial results for the quarter ended March 31, 2020. The registrant is an emerging growth company incorporated in Delaware with its principal executive offices in Rockville, Maryland.

Key Financial Metrics

The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were issued in a press release (Exhibit 99.1) but does not reproduce the financial data within the body of the 8-K itself.

Material Changes

The filing text does not provide specific details regarding material changes versus the prior comparable period. It references the attached press release for the full announcement of results.

Guidance, Outlook, and Risks

The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release dated May 7, 2020) for actual revenue, net loss, and cash position figures.
  • Verify the company's cash runway and burn rate as disclosed in the referenced press release.
  • Confirm any updates to clinical trial progress or regulatory milestones mentioned in the full press release.
  • Check for any subsequent filings that may provide more detailed financial statements.